scholarly journals The Cross-Talk Between the Dopaminergic and the Immune System Involved in Schizophrenia

2020 ◽  
Vol 11 ◽  
Author(s):  
Pia M. Vidal ◽  
Rodrigo Pacheco
Keyword(s):  
Immune System ◽  
Cross Talk ◽  
The Cross

scholarly journals Targeting neuro–immune communication in neurodegeneration: Challenges and opportunities

2018 ◽  
Vol 215 (11) ◽  
pp. 2702-2704 ◽  
Author(s):  
Aleksandra Deczkowska ◽  
Michal Schwartz
Keyword(s):  
Immune System ◽  
Cross Talk ◽  
Immune Cells ◽  
Therapeutic Approach ◽  
Neurological Diseases ◽  
Challenges And Opportunities ◽  
The Cross ◽  
The Brain

Immune cells patrol the brain and can support its function, but can we modulate brain–immune communication to fight neurological diseases? Here, we briefly discuss the mechanisms orchestrating the cross-talk between the brain and the immune system and describe how targeting this interaction in a well-controlled manner could be developed as a universal therapeutic approach to treat neurodegeneration.

The cross talk between microbiota and the immune system: metabolites take center stage

2014 ◽  
Vol 30 ◽  
pp. 54-62 ◽  
Author(s):  
Hagit Shapiro ◽  
Christoph A Thaiss ◽  
Maayan Levy ◽  
Eran Elinav
Keyword(s):  
Immune System ◽  
Cross Talk ◽  
Center Stage ◽  
The Cross

scholarly journals A Proteomic View of the Cross-Talk Between Early Intestinal Microbiota and Poultry Immune System

2020 ◽  
Vol 11 ◽  
Author(s):  
D. R. Rodrigues ◽  
K. M. Wilson ◽  
M. Trombetta ◽  
W. N. Briggs ◽  
A. F. Duff ◽  
...  
Keyword(s):  
Immune System ◽  
Intestinal Microbiota ◽  
Cross Talk ◽  
The Cross

Potential immunotherapy for Alzheimer disease and age-related dementia

2019 ◽  
Vol 21 (1) ◽  
pp. 21-25 ◽  
Keyword(s):  
Immune System ◽  
Alzheimer Disease ◽  
Cross Talk ◽  
Immune Checkpoint ◽  
Short Review ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
New Approach ◽  
Age Related ◽  
The Brain

Emerging results support the concept that Alzheimer disease (AD) and age-related dementia are affected by the ability of the immune system to contain the brain's pathology. Accordingly, well-controlled boosting, rather than suppression of systemic immunity, has been suggested as a new approach to modify disease pathology without directly targeting any of the brain's disease hallmarks. Here, we provide a short review of the mechanisms orchestrating the cross-talk between the brain and the immune system. We then discuss how immune checkpoint blockade directed against the PD-1/PD-L1 pathways could be developed as an immunotherapeutic approach to combat this disease using a regimen that will address the needs to combat AD.

Sign in / Sign up

Export Citation Format

Share Document